中國抗體-B(03681.HK)向一名僱員授出1006.2萬份受限制股份單位
格隆匯6月5日丨中國抗體-B(03681.HK)公佈,於2020年6月5日,公司已議決根據於2019年10月18日有條件採納並於2019年11月12日生效的受限制股份單位計劃授出受限制股份單位。受限制股份單位計劃旨在通過向集團董事、高級管理層及僱員提供擁有公司股權的機會,激勵彼等對集團作出貢獻,並吸引、激勵及挽留熟練且有經驗的人員致力於集團的未來發展及擴張。
同日,公司根據受限制股份單位計劃就總計1006.2萬股公司普通股向公司一名僱員授出1006.2萬份受限制股份單位,佔於本公告日期公司已發行股本總額的1%。於授出的同一日,受限制股份單位歸屬於承授人,而中央證券已將1006.2萬股公司普通股轉讓予承授人。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.